Gish Biomedical cuts staff by nearly a quarter:
This article was originally published in Clinica
Gish Biomedical is to cut its work force by 23%, in response to declining sales and earnings. Earlier this month the company, which manufactures disposable surgical devices, warned it would have to make management changes (see Clinica No 877, p 12). It is now looking for further ways to reduce running costs and improve its competitiveness. The staff cuts will cost Irving, California-based Gish around $100,000 to implement. The company maintains that its balance sheet is strong and that it has substantial cash reserves.
You may also be interested in...
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”